Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis

被引:170
作者
Ciurea, Stefan O.
Merchant, Delwin
Mahmud, Nadim
Ishii, Takefumi
Zhao, Yan
Hu, Wenyang
Bruno, Edward
Barosi, Giovanni
Xu, Mingjiang
Hoffman, Ronald
机构
[1] Univ Illinois, Coll Med Chicago, COMRB, Hematol Oncol Sect,Dept Med, Chicago, IL 60612 USA
[2] Policlin San Matteo, IRCCS, I-27100 Pavia, Italy
[3] Myeloproliferat Dis Res Consortium, New York, NY USA
关键词
D O I
10.1182/blood-2006-12-064626
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to investigate the biologic processes underlying and resulting from the megalkaryocytic hyperplasia that characterizes idiopathic myelofibrosis (IMF), peripheral blood CD34(+) cells isolated from patients with IMF, polycythemia vera (PV), and G-CSF-mobilized healthy volunteers were cultured in the presence of stem cell factor and thrombopoietin. IMF CD34(+) cells generated 24-fold greater numbers of megakaryocytes (MKs) than normal CD34(+) cells. IMF MKs were also shown to have a delayed pattern of apoptosis and to overexpress the antiapoptotic protein bcl-xL. MK hyperplasia in IMF is, therefore, likely a consequence of both the increased ability of IMF progenitor cells to generate MKs and a decreased rate of MK apoptosis. Media conditioned (CM) by CD61(+) cells generated in vitro from CD34(+) cells were then assayed for the levels of growth factors and proteases. Higher levels of transforming growth factor-beta (TGF-beta) and active matrix metalloprotein-ase-9 (MMP9) were observed in media conditioned with IMF CD61(+) cells than normal or PV CD61(+) cells. Both normal and IMF CD61(+) cells produced similar levels of VEGF. MK-derived TGF-B and MMP-9, therefore, likely contribute to the development of many pathological epiphenomena associated with IMF.
引用
收藏
页码:986 / 993
页数:8
相关论文
共 42 条
  • [1] Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines
    Barosi, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2954 - 2970
  • [2] The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia
    Barosi, G
    Ambrosetti, A
    Finelli, C
    Grossi, A
    Leoni, P
    Liberato, NL
    Petti, MC
    Pogliani, E
    Ricetti, M
    Rupoli, S
    Visani, G
    Tura, S
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (04) : 730 - 737
  • [3] Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia
    Barosi, G
    Viarengo, G
    Pecci, A
    Rosti, V
    Piaggio, G
    Marchetti, M
    Frassoni, F
    [J]. BLOOD, 2001, 98 (12) : 3249 - 3255
  • [4] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter, EJ
    Scott, LM
    Campbell, PJ
    East, C
    Fourouclas, N
    Swanton, S
    Vassiliou, GS
    Bench, AJ
    Boyd, EM
    Curtin, N
    Scott, MA
    Erber, WN
    Green, AR
    [J]. LANCET, 2005, 365 (9464) : 1054 - 1061
  • [5] Transforming growth factor-β signal transduction in angiogenesis and vascular disorders
    Bertolino, P
    Deckers, M
    Lebrin, F
    ten Dijke, P
    [J]. CHEST, 2005, 128 (06) : 585S - 590S
  • [6] Bock O, 2005, HAEMATOLOGICA, V90, P133
  • [7] BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH
    BOISE, LH
    GONZALEZGARCIA, M
    POSTEMA, CE
    DING, LY
    LINDSTEN, T
    TURKA, LA
    MAO, XH
    NUNEZ, G
    THOMPSON, CB
    [J]. CELL, 1993, 74 (04) : 597 - 608
  • [8] CASTROMALASPINA H, 1981, BLOOD, V57, P781
  • [9] Prominent role of TGF-β1 in thrombopoietin-induced myelofibrosis in mice
    Chagraoui, H
    Komura, E
    Tulliez, M
    Giraudier, S
    Vainchenker, W
    Wendling, F
    [J]. BLOOD, 2002, 100 (10) : 3495 - 3503
  • [10] Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia
    Chou, JM
    Li, CY
    Tefferi, A
    [J]. LEUKEMIA RESEARCH, 2003, 27 (06) : 499 - 504